1 – 7 of 7
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
The α2β1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study.
(
- Contribution to journal › Article
- 2014
-
Mark
The C-Terminal Domain of Chondroadherin: A New Regulator of Osteoclast Motility Counteracting Bone Loss
(
- Contribution to journal › Article
- 2013
-
Mark
Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss
(
- Contribution to journal › Article
- 2010
-
Mark
The N-terminal domain of the bone protein PRoline/arginine-rich End Leucine-rich repeat Protein (PRELP) impairs osteoclast formation by a new mechanism inhibiting NF-kappaB signaling
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappa B inhibitor that impairs osteoclastogenesis
(
- Contribution to journal › Article
- 2008
-
Mark
The matrix PROLINE/Arginine-Rich end leucin-rich repeat protein (PRELP) impairs osteoclastogenesis by inhibiting NF-kappaB activity
(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Polymorphisms of the CLCN7 gene are associated with BMD in women
(
- Contribution to journal › Article